Fennec Pharmaceuticals (FENC) Non-Current Debt (2021 - 2022)

Fennec Pharmaceuticals (FENC) posted Non-Current Debt of $25.0 million for Q3 2022, up 525.0% on a QoQ basis from $4.0 million in Q2 2022.

Fennec Pharmaceuticals (FENC) Non-Current Debt (2021 - 2022) Analysis & Trends

Fennec Pharmaceuticals' Non-Current Debt history runs 2 years deep, the most recent figure standing at $25.0 million for Q3 2022.

Quarterly Non-Current Debt changed N/A year-over-year to $25.0 million in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $25.0 million (changed N/A YoY) and the FY2021 annual result came in at $5.0 million, changed N/A from the prior year.
Non-Current Debt was $25.0 million for Q3 2022 at Fennec Pharmaceuticals, up from $4.0 million in the prior quarter.
Across five years, Non-Current Debt topped out at $25.0 million in Q3 2022 and bottomed at $4.0 million in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	105.94 Mn
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	842.92 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	1.99 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Fennec Pharmaceuticals	346.75 Mn	309.97 Mn	12.01 Mn	-

Download Data